Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Phathom Pharmaceuticals, a clinical-stage biopharmaceutical company developing vonoprazan-based therapies, filed this Current Report on September 20, 2021, reporting transactions entered into on September 17, 2021. The filing concerns a new secured term-loan facility, retirement of the company’s prior Silicon Valley Bank term loan, and issuance of an equity warrant.
Financial and capital structure details
- New financing: A Loan and Security Agreement with Hercules Capital and other lenders provides for up to $200.0 million of term loans in four tranches.
- Funded at closing: The first tranche of $100.0 million was funded on September 17, 2021.
- Use of proceeds: Proceeds are intended for working capital and general corporate purposes. Approximately $54 million was used to repay and retire the prior SVB Term Loan in full.
- Interest: Cash interest accrues at the greater of 5.50% or the Wall Street Journal Prime Rate plus 2.25%. Additional payment-in-kind interest accrues at 3.35% annually.
- Maturity and amortization: The loan matures on October 1, 2026. Interest-only payments are permitted through October 1, 2024, with potential extensions to October 1, 2025 or October 1, 2026 if specified development and regulatory milestones are achieved and no default exists. Thereafter, principal and interest are payable in equal monthly installments.
- Additional borrowing capacity: Up to $50.0 million may become available upon successful Phase 3 erosive esophagitis results; an additional $25.0 million may become available upon specified H. pylori regulatory and erosive esophagitis filing milestones; and a further $25.0 million may become available upon the same milestone conditions, subject to specified availability periods.
- Collateral: The company granted Hercules a senior security interest in substantially all company property, including intellectual property.
- Warrant: Phathom issued Hercules a warrant to purchase 74,783 shares of common stock at an exercise price of $33.43 per share. The warrant is exercisable for seven years from issuance. Future funded advances are subject to warrants equal to 2.5% of the aggregate funded advances.
The filing does not provide revenue, profit, cash-flow, margin, or liquidity balances for the reporting period.
Material changes versus the prior comparable period
- Phathom replaced its prior SVB Term Loan with a new Hercules-led facility and received $100.0 million of initial funding.
- The company increased potential debt financing capacity to $200.0 million, subject to development, regulatory, and other conditions.
- The transaction added secured debt, payment-in-kind interest obligations, financial covenants, and potential equity dilution through the warrant.
Guidance, outlook, risks, contingencies, and unusual items
- Availability of the unfunded tranches depends on specified Phase 3 efficacy and safety results, FDA approvals, regulatory filings, and other lender conditions.
- The loan agreement includes customary covenants, events of default, fees, prepayment provisions, and a requirement to maintain specified levels of Qualified Cash.
- Beginning May 15, 2023, the company is subject to a trailing three-month net product-revenue covenant based on sales of vonoprazan and products containing vonoprazan.
- The revenue covenant may be waived if Qualified Cash equals at least 60.0% of outstanding term-loan principal before the specified Third Performance Milestone, or 35.0% after that milestone, or if the company’s market capitalization is at least $900.0 million.
- Failure to achieve development or regulatory milestones could limit access to additional financing and prevent extensions of the interest-only period.
- The warrant was issued in an unregistered transaction relying on the Securities Act Section 4(a)(2) exemption.
Important facts for investors to verify
- Whether the additional loan tranches became available and were funded after the filing date.
- Current outstanding principal, accrued payment-in-kind interest, cash interest rate, and remaining liquidity.
- Achievement of the Phase 3, FDA approval, and filing milestones governing additional borrowing and interest-only extensions.
- Compliance with Qualified Cash and future vonoprazan revenue covenants.
- The final Loan Agreement and warrant terms, which the filing stated would be included as exhibits to the company’s next Form 10-Q.